Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals
The healthcare and the marijuana sectors are probably the only two sectors in the limelight right now. All eyes are on the healthcare sector to finally find a cure to put an end to the coronavirus crisis. Meanwhile, the cannabis industry is attracting consumers hoping for some relief with the help of marijuana. Medical marijuana is known to have helped with many health issues and has even worked better than conventional medicines in some cases.
Cannabidiol (CBD)-based products are in huge demand globally, and these two pharmaceutical-biotech companies are known for their CBD-based products. Both Cambridge, U.K.-based GW Pharmaceuticals (NASDAQ: GWPH) and Massachusetts, U.S.-based Corbus Pharmaceuticals Holdings' (NASDAQ: CRBP) stocks are up double-digits to 29.4% and 27.2% year to date, while the market is down by 0.66% as tracked by the SPDR S&P 500 ETF. Here's what's behind the surge and why one of these companies is the better bet.
Image Source: Getty Images.
Source Fool.com
